Illumina

Illumina, Telegraph Hill Partners launch Verogen

Tuesday, August 29, 2017

Illumina announced plans with Telegraph Hill Partners (THP), a San Francisco-based venture capital and growth equity firm, to establish Verogen. The independent new company has certain exclusive rights to provide Illumina’s forensic sequencing technology to forensic customers, including for criminal casework and other human and nonhuman forensic applications. The creation of Verogen enables an unprecedented focus on accelerating growth of Illumina’s leading next-generation sequencing (NGS) technology in the forensic genomics market.

[Read More]

Illumina, Bio-Rad launch solution for single-cell genomic sequencing

Tuesday, January 10, 2017

Illumina and Bio-Rad Laboratories launched the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.

[Read More]

Philips, Illumina partner on integrated genomics solutions for oncology

Monday, January 9, 2017

Royal Philips, a global leader in health technology, and Illumina, a global leader in DNA sequencing and array-based technologies, has announced a strategic collaboration that aims to integrate Illumina’s sequencing systems for large-scale analysis of genetic variation and function and Philips’ IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the U.S. that want to develop precision medicine programs in oncology.

[Read More]

Illumina hires Garret Hampton to head Clinical Genomics Unit

Tuesday, January 3, 2017

Illumina, continuing its strategy to bring the power of genomics into clinical applications, has named one of the world’s top clinical genomics experts to head its clinical genomics unit. Garret Hampton, Ph.D., will join as executive vice president of Clinical Genomics for the company, starting January 9, 2017.

[Read More]

Illumina launches iHope Program for pediatric undiagnosed genetic diseases

Friday, December 2, 2016

Illumina has announced the iHope program, a philanthropic initiative aimed at identifying the genetic causes of undiagnosed rare diseases in children. With initial program partners Foundation for the Children of the CaliforniasRare Genomics Institute and UCSF Benioff Children’s Hospital San Francisco, selected patients in financial need will receive clinical whole-genome sequencing performed by the Illumina Clinical Services Laboratory. Through whole-genome sequencing—the process of determining the order of all the DNA in a person’s body—Illumina and the iHope program partners strive to end years-long diagnostic odysseys of unnecessary and inconclusive testing for these children and their families.

[Read More]